Tuesday, June 07, 2016 12:55:29 PM
Valeant: Still the Sick Man of Pharmaceuticals
The clouds hanging over Valeant’s prospects just won’t go away. The drugmaker’s quarterly results have dashed any immediate hopes that its business is turning around.
VRX BIIB ALXN SRPT TRU NH LDRH NAV
The clouds hanging over Valeant’s prospects just won’t go away. The drugmaker’s quarterly results have dashed any immediate hopes that its business is turning around.
VRX BIIB ALXN SRPT TRU NH LDRH NAV
My post is for Your Eyes only and my entertainment
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
